Bone marrow transplantation in chronic myelogenous leukemia;Trasplante de medula osea en leucemia mieloide cronica

Medicina

Volumn 59, Issue 1, 1999, Pages 1-10

  Milone, Jorge H ^b   Bordone, Javier ^b   Etchegoyen, Orlando ^b   Napal, Juan ^b   Prates, Maria Virginia ^b   Morales, Victor H ^a  

^a Inst de Trasplante de Medula Osea   (Argentina)

^b NONE

Author keywords

Bone marrow transplantation; Chronic myelogenous leukemia

Indexed keywords

BCR ABL PROTEIN; MICROSATELLITE DNA;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC MYELOID LEUKEMIA; FEMALE; FOLLOW UP; GENETICS; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; REMISSION; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

ACTUARIAL ANALYSIS; ADULT; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM, RESIDUAL; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY;

EID: 0040809573     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Silver R. Chronic myeloid leukemia-A perspective of clinical and biologic issues of the chronic phase. Hematol Oncol Clin NA 1990; 4: 319-35.
2. Canellos GP. Chronic granulocyte leukemia. Med Clin NA 1988; 60: 1001-81.
3. Golde DW, Champlin RE. Chronic mylogenous leukemia: Recent Advances. Blood 1985; 65: 1039-47.
4. Fialkow PJ, Jacobson RJ, Papayannoupoulou T. Chronic myelocytic leukemia. Clonal origin in stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977; 63: 125-30.
5. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocyte leukemia. Science 1960; 132: 1497-9.
6. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa stainning. Nature 1973; 243: 290-3.
7. Sandberg AA, Gemmill RM, Hecht BK, Hecht F. The Philadelphia chromosome: A model of cancer and molecular cytogenetic. Cancer Genet Cytogenet 1986; 21: 129-46.
8. De Klein A, Van Kessel A, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D. A celular oncogene is traslocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 1982; 300: 765-7.
9. Groffen J, Stephenson JE, Hiesterkamip N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosome breakpoints are clustered whithin a limited region bcr on chromosome 22. Cells, 1984; 36: 93-9.
10. Schwartz JH, Cannellos GP. Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia. Blood 1975; 46: 11-6.
11. Rushing D, Goldman A, Gibbs G, Howe R, Kennedy BJ. Hidroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. Am J Clin Oncol 1982; 5: 307-13.
12. Kennedy BJ. The evolution of hidroxyurea therapy in chronic myelogenous leukemia. Semin Oncol 1992; 19: (Suppl 9) 21-6.
13. Kloke O, Niederle N, Qiu JY, Wandi U, Moritz T, Nagel-Hiemke M, et al. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukemia. Br J Haematol 1993; 83: 399-403.
14. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interleron-alpha therapy. The Leukemia Service. Ann Inter Med 1995; 122: 254-61.
15. Hellmann R, Heimpel H, Hasford J, Kalb HJ, Pralle H, Hossfeld DK, et al. The German CML Study Group. Randomized comparison of interferon-apha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064-77.
16. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomized multicentre trial of interferon-alpha for chronic myeloid leukemia. Improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-7
17. Malinge MC, Mahon FX, Delfau MH, Daheron L, Kitzis A, Guilhot F, et al. Quantitative determination of the hybrid bcr/abl RNA in patients with chronic myelogenous leukaemia under interferon therapy. Br J Haematol 1992; 82 (4): 701-7.
18. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
19. Kwok S, Higushi R. Avoiding false positives with PCR. Nature 1989; 339: 237-8.
20. Rowe JM, Ciobanu N, Ascensao J, Stadtmauer EA, Weiner RS, Schenkein DP, et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the eastern cooperative oncology group (ECOG). Ann Inter Med 1994; 120: 143-58.
21. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Eng J. Med 1994; 330: 820-5.
22. Dexter TM, Chang J. New strategies for the treatment of chronic myeloid leukemia. Blood 1994; 84: 673-5.
23. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoro A, et al. A randomized trial comparing interferon α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86: 906-16.
24. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger W, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155-63.
25. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, et al. Bone Marrow Transplantation for chronic myelogenous leukemia in chronic phase: Increase risk of relapse associated with T-cell depletion. Ann Inter Med 1988; 108: 806-14.
26. Thomas ED, Clift RA. Indications for Marrow Transplantation in chronic myelogenous leukemia. Blood 1989; 73: 861-4.
27. Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G, et al. Bone Marrow Transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1993; 12: 509-16.
28. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954-6.
29. Gale RP, Hehlmann R, Zhang MJ, Hasford J, Goldman JM, Heimpel H, et al. Survival with bone marrow transplantation versus Hydroxyurea or Interferon for chronic myelogenous Leukemia. Blood 1998; 91: 1810-9.
30. Mc Cann SR, Lawler M. Mixed chimaerism: detection and significance following BMT. Bone Marrow Transplant 1993; 11: 91-4.
31. Socie G, Lawler M, Gluckman E, Mc Cann SR, Brison O. Studies on hemopoietic chimerism following allogeneic bone marrow transplantation in the molecular era. Leukemic Res 1995; 19: 497-504.
32. Petz LD, Yam P, Wallace RB, Stock AD, de Lange G, Knowlton RG, et al. Mixed hematopoietic chimerism following bone marrow transplantation in leukemic HLA matched patient: a cytogenetics documentation. Blood 1987; 70: 1331-7.
33. Bertheas MF, Maraninchi D, Lafage M, Fraisse J, Blaise D, Stoppa AM, et al. Partial chimerism after T-cell depleted allogeneic bone marrow transplantation in leukemic HLA matched patients: a cytogenetics documentation. Blood 1988; 72: 89-93.
34. Roy DC, Tantravahi R, Murray C, Dear K, Gorgone B, Anderson KC, et al. Natural history of mixed chimerism after bone marrow transplantation with CD 6 depleted allogenic marrow: a stable equilibrium. Blood 1990; 75: 296-304.
35. Offit K, Burns JP, Cunningham I, Jhanwar SC, Black P, Kernan NA, et al. Cytogenetics analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T cell depleted bone marrow transplantation. Blood 1990; 75: 1346-55.
36. Lawler M, Humphries P, Mc Cann SR. Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction. Blood 1991; 77: 2504-2514.
37. Gardiner N, Lawler M, O'Riordan J, De Arce M, Humphries P, McCann SR. Persistent donor chimaerism is consistent with disease free survival following BMT for chronic myeloid leukemia. Bone Marrow Transplant 1997; 20: 235-41.
38. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic Myelogenous Leukemia: A Concise Update. Blood 1993; 82: 691-703.
39. Cross NC, Hughes TP, Feng L, O'Shea P, Bungey J, Marks Dl, et al. Minimal residual disease after allogenic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft versus host disease and relapse. Br J Haematol 1993; 84: 67-74.
40. Roth MS, Antin JH, Bingham EL, Ginsburg D. Detection of Philadelphia Chromosome-positive cells by the Polymerase Chain Reaction following Bone Marrow Transplant for chronic myelogenous leukemia. Blood 1989; 74: 882-5.
41. Morgan GJ, Hughes T, Janssen JW, Gow J, Guo AP, Goldman JM, et al. Polymerase chain reaction for detection of residual disease. Lancet 1989; 1: 928-9.
42. Sawyers CL, Timson L, Kawasaki ES, Clack SS, Witte ON, Champlin R, et al. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc Natl Acad Sci 1990, 87: 563-7.
43. Hughes TP, Morgan GJ, Martiat P, Goldman JM. Detection of residual leukemia after bone marrow transplantation for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991; 77: 874-8.
44. Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collin S, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogenic marrow transplantation for chronic myeloid leukemia. Blood 1995; 85: 2632-8.
45. Martiat P, Maisin D, Philippe M, Ferrant A, Michaux JL, Cassiman JJ, et al. Detection of residual bcr/abl transcripts in chronic myeloid leukemia patients in complete remision using the polymerase chain reaction and nested primers. Br J Haematol 1990; 75: 355-8.
46. Gabert J, Thuret I, Lafage M, Carcassonne Y, Maraninchi D, Mannoni P. Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukemia patients after bone marrow transplantation. Lancet 1989; 2: 1125-8.
47. Miyamura K, Barrett AJ, Kodera Y, Saito H. Minimal residual disease after Bone Marrow Transplantation fo chronic myeloid leukemia and implication for graft versus leukemia effect: a review of recent results. Bone Marrow Transplant 1994; 14: 201-9.
48. Lange W, Snyders DS, Castro R, Rossi JJ, Blume KG. Detection by enzymatic amplification of bcr/abl mRNA in peripheral blood and bone marrow cells of patients with chronic myelogenous leukemia. Blood 1989; 73: 1735-41.
49. Pignon JM, Henni T, Amselen S, Vidaud M, Duquesnoy P, Vernant JP, et al. Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivor after bone marrow transplantation for chronic myeloid leukemia. Leukemia 1990; 4: 83-6.
50. Lee M, Khouri I, Champlin R, Kartarjian H, Talpaz M, Tujillo J, et al. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcription in chronic myelogenous leukaemia following allogenic bone marrow transplantation. Br J Haematol 1992; 82: 708-14.
51. Delfau MH, Kerckaert JP, D'Hooghe MC, Fernaux P, Lai JL, Janet JP, et al. Detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reation. Leukemia 1990; 4: 1-5.
52. Snyder DS, Rossi JJ, Wang JI, Sniecinski IJ, Slovak ML, Wallace RB, et al. Persistence of bcr-abl gene expresion following bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Transplantation 1991; 51: 1033-40.
53. Morgan GJ, Wiedemann LM. The clinical application of molecular techniques in Philadelphia-positive leukaemia. Br J Haematol 1992; 80: 1-5.
54. Hughes TP, Goldman JM. Biological importance of residual leukaemia cells after BMT for CML: does the polymerase chain reaction help? Bone Marrow Transplant 1990; 5: 3-6.